This is an info Alert.
  • Home
  • Product
  • Blog
  • Contact

Discover laboratory and life science products for your research. Search our catalog by product name, keyword or catalog number and find the right solution for your laboratory.

Search thousands of research products

Product information & research resources

Support for your product inquiries

Products
All productsSearch products
Resources
ArticlesFAQs
Company
About usContact us
Legal
Terms & conditionsPrivacy policy

© 2026 Gentaur. All rights reserved.
ProductsArticlesContact
0
  1. Home
  2. Products
  3. TMPRSS2 Mouse Monoclonal Antibody [A6D9]
1/0

TMPRSS2 Mouse Monoclonal Antibody [A6D9]

Product ID: 8228210


Gentaur Catalog Number

GTR09936351
Select size

100 µL

$695.11
​
Selected
100 µL

$695.11

1

Transmembrane protease, serine 2 is an enzyme that in humans is encoded by the TMPRSS2 gene. This gene encodes a protein that belongs to the serine protease family. The encoded protein contains a type II transmembrane domain, a receptor class A domain, a scavenger receptor cysteine-rich domain and a protease domain. Serine proteases are known to be involved in many physiological and pathological processes. This gene was demonstrated to be up-regulated by androgenic hormones in prostate cancer cells and down-regulated in androgen-independent prostate cancer tissue. The protease domain of this protein is thought to be cleaved and secreted into cell media after autocleavage. The biological function of this gene is unknown. TMPRSS2 protein's function in prostate carcinogenesis relies on overexpression of ETS transcription factors, such as ERG and ETV1, through gene fusion. TMPRSS2-ERG fusion gene is the most frequent, present in 40% - 80% of prostate cancers in humans. ERG overexpression contributes to development of androgen-independence in prostate cancer through disruption of androgen receptor signaling. Some coronaviruses, e.g. SARS-CoV-1, MERS-CoV, and SARS-CoV-2 are activated by TMPRSS2 and can thus be inhibited by TMPRSS2 inhibitors. SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option.